Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Stock Overview
Explore Ultragenyx Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.6B
P/E Ratio
-4.82
EPS (TTM)
$-5.83
ROE
-1.86%
RARE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ultragenyx Pharmaceutical Inc. (RARE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 32.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $55.85.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.82 and a market capitalization of 2.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.